Fate Financial Statements From 2010 to 2024

FATE Stock  USD 4.30  0.24  5.29%   
Fate Therapeutics financial statements provide useful quarterly and yearly information to potential Fate Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Fate Therapeutics financial statements helps investors assess Fate Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Fate Therapeutics' valuation are summarized below:
Gross Profit
-224.2 M
Profit Margin
(2.53)
Market Capitalization
516.6 M
Enterprise Value Revenue
7.0204
Revenue
63.5 M
There are over one hundred nineteen available fundamental signals for Fate Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to verify all of Fate Therapeutics' prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. As of April 25, 2024, Market Cap is expected to decline to about 349.7 M. In addition to that, Enterprise Value is expected to decline to about 408.2 M

Fate Therapeutics Total Revenue

66.71 Million

Check Fate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fate main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.2 M, Interest Expense of 7.1 M or Selling General Administrative of 85.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.5, Dividend Yield of 0.06 or PTB Ratio of 0.95. Fate financial statements analysis is a perfect complement when working with Fate Therapeutics Valuation or Volatility modules.
  
This module can also supplement Fate Therapeutics' financial leverage analysis and stock options assessment as well as various Fate Therapeutics Technical models . Check out the analysis of Fate Therapeutics Correlation against competitors.
For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.

Fate Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets310.1 M506.2 M265.5 M
Slightly volatile
Short and Long Term Debt Total108.7 M103.5 M43.6 M
Slightly volatile
Other Current Liabilities18.9 M27.5 M16.2 M
Slightly volatile
Total Current Liabilities36.6 M39.1 M31.5 M
Slightly volatile
Other Liabilities4.2 M4.4 M10.4 M
Slightly volatile
Property Plant And Equipment Net166.4 M158.5 M37.9 M
Slightly volatile
Current Deferred Revenue650.8 K685 K7.2 M
Slightly volatile
Accounts PayableM4.7 M3.6 M
Slightly volatile
Cash39.8 M41.9 M73.4 M
Slightly volatile
Non Current Assets Total183.4 M174.7 M71.6 M
Slightly volatile
Non Currrent Assets Other8.5 KK19.9 M
Slightly volatile
Other Assets0.951.09.9 M
Slightly volatile
Cash And Short Term Investments224.2 M315.2 M192 M
Slightly volatile
Common Stock Total Equity115.9 K110.4 K54.3 K
Slightly volatile
Common Stock Shares Outstanding54.2 M98.4 M46.9 M
Slightly volatile
Liabilities And Stockholders Equity310.1 M506.2 M265.5 M
Slightly volatile
Non Current Liabilities Total63.3 M98.7 M57.7 M
Slightly volatile
Other Current Assets14.3 M13.6 M5.6 M
Slightly volatile
Total Liabilities99.9 M137.8 M89.2 M
Slightly volatile
Property Plant And Equipment Gross216.4 M206.1 M47.3 M
Slightly volatile
Total Current Assets234.9 M331.5 M201.2 M
Slightly volatile
Short Term Debt4.6 M6.2 MM
Slightly volatile
Common Stock58.1 K99 K49.7 K
Slightly volatile
Property Plant Equipment212.6 M202.5 M54.3 M
Slightly volatile
Net Tangible Assets584.4 M556.5 M247 M
Slightly volatile
Capital Surpluse1.7 B1.7 B649.5 M
Slightly volatile
Deferred Long Term LiabilitiesM8.3 M3.9 M
Slightly volatile
Long Term Debt Total9.4 M11.2 M13.4 M
Slightly volatile
Short and Long Term Debt2.7 M2.8 M3.7 M
Very volatile
Non Current Liabilities Other721.9 K920 K552.5 K
Slightly volatile
Net Invested Capital381.5 M368.4 M230.2 M
Slightly volatile
Net Working Capital331.6 M292.4 M205.5 M
Slightly volatile
Net Receivables2.6 M2.7 M4.3 M
Slightly volatile
Capital Stock98.8 K102 K78.8 K
Slightly volatile
Capital Lease Obligations99.4 M103.5 M52.9 M
Slightly volatile

Fate Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization19.2 M18.3 M4.4 M
Slightly volatile
Interest Expense7.1 M6.7 M2.5 M
Slightly volatile
Selling General Administrative85.5 M81.4 M29.5 M
Slightly volatile
Other Operating Expenses122.6 M241.1 M105.7 M
Slightly volatile
Research Development91.4 M143.4 M78.7 M
Slightly volatile
Cost Of Revenue17.4 M18.3 M32.7 M
Pretty Stable
Total Operating Expenses121 M222.9 M104.4 M
Slightly volatile
Interest Income16.4 M15.7 M4.1 M
Slightly volatile
Reconciled Depreciation19.2 M18.2 M4.7 M
Slightly volatile
Selling And Marketing Expenses1.6 M1.8 MM
Slightly volatile

Fate Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation45.6 M43.5 M19.4 M
Slightly volatile
Begin Period Cash Flow89.3 M61.3 M77.1 M
Slightly volatile
Other Cashflows From Financing Activities118.3 M112.7 M28.4 M
Slightly volatile
Depreciation19.2 M18.3 M4.6 M
Slightly volatile
Capital Expenditures9.5 M6.2 M8.1 M
Slightly volatile
Total Cash From Financing Activities80.8 K85 K85.8 M
Slightly volatile
End Period Cash Flow39.8 M41.9 M76.5 M
Slightly volatile
Change To Netincome62.5 M59.6 M19.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.55.793263.1852
Pretty Stable
Dividend Yield0.060.06750.0735
Slightly volatile
Days Sales Outstanding14.8815.66145.9586
Pretty Stable
Stock Based Compensation To Revenue0.720.6840.844
Slightly volatile
Days Of Inventory On Hand0.00.00.0
Slightly volatile
Payables Turnover3.683.874112.0432
Slightly volatile
Sales General And Administrative To Revenue1.221.2822.7322
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue2.142.25736.6697
Slightly volatile
Cash Per Share2.963.20263.4489
Slightly volatile
Capex To Operating Cash Flow0.06320.04650.0727
Slightly volatile
Days Payables Outstanding14394.214883.6076
Slightly volatile
Income Quality0.840.82190.7781
Pretty Stable
Current Ratio5.488.48066.4245
Pretty Stable
Receivables Turnover24.4723.306310.3812
Slightly volatile
Graham Number10.0411.736312.4805
Very volatile
Revenue Per Share0.680.64560.3126
Slightly volatile
Interest Debt Per Share0.581.05210.7121
Slightly volatile
Debt To Assets0.230.20450.2399
Slightly volatile
Operating Cycle14.8815.66150.2938
Pretty Stable
Days Of Payables Outstanding14394.214883.6076
Slightly volatile
Ebt Per Ebit1.140.90611.0464
Very volatile
Quick Ratio5.378.13176.2865
Pretty Stable
Net Income Per E B T1.061.040.9943
Very volatile
Cash Ratio1.021.0714.2218
Slightly volatile
Days Of Inventory Outstanding0.00.00.0
Slightly volatile
Days Of Sales Outstanding14.8815.66145.9586
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.861.04651.0592
Pretty Stable
Fixed Asset Turnover0.380.40081.1523
Slightly volatile
Capital Expenditure Coverage Ratio20.4221.4957829
Slightly volatile
Debt Ratio0.230.20450.2399
Slightly volatile
Price Sales Ratio5.55.793263.1852
Pretty Stable
Asset Turnover0.08790.12550.0821
Pretty Stable

Fate Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap349.7 M368.1 M1.2 B
Slightly volatile

Fate Fundamental Market Drivers

Cash And Short Term Investments315.2 M

Fate Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Fate Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Fate Therapeutics income statement, its balance sheet, and the statement of cash flows. Fate Therapeutics investors use historical funamental indicators, such as Fate Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Fate Therapeutics investors may use each financial statement separately, they are all related. The changes in Fate Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fate Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Fate Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Fate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue685 K650.8 K
Total Revenue63.5 M66.7 M
Cost Of Revenue18.3 M17.4 M
Stock Based Compensation To Revenue 0.68  0.72 
Sales General And Administrative To Revenue 1.28  1.22 
Research And Ddevelopement To Revenue 2.26  2.14 
Capex To Revenue(0.1)(0.10)
Revenue Per Share 0.65  0.68 
Ebit Per Revenue(2.80)(2.94)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:
Check out the analysis of Fate Therapeutics Correlation against competitors.
For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Fate Stock analysis

When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.64)
Revenue Per Share
0.646
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.18)
Return On Equity
(0.38)
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.